Urigen is a private specialty pharmaceutical company focused on the clinical development of innovative products in the field of urology and women's health. Urigen's experienced management has teamed up with Professor Lowell Parsons, M.D. to commercialize a novel treatment for pelvic pain of bladder origin.

U101 is a proprietary intravesical (bladder instillation) therapy for pelvic pain. Initial published clinical experience (open-label, prospective) has shown efficacy and safety. Estimates are that over 15 million women in North America suffer from pelvic pain of bladder origin.

CAPRA promotes partnerships between Canadian companies which want to develop businesses in Asia, and Asian companies aiming to establish a business presence in North America.  CAPRA’s focus is in life sciences - especially biotechnology and medical devices.  Specifically, CAPRA can:

• Arrange introductions for Canadian companies with potential strategic partners and/or acquisition candidates in Asia, and vice versa
• Develop strategies for tackling Asian markets, in alliance with R&D, manufacturing, and distribution companies based in Asia
• Through its alliance with a Chinese company, facilitate timely approvals of medical devices in China for Canadian manufacturers
• Assist with the process of securing business travel visas for Chinese companies visiting Canada
• Identify appropriate distribution channels for your business, both in Asia and Canada